ASCPT Announces New CEO Abigail W. Gorman

The American Society for Clinical Pharmacology & Therapeutics (ASCPT) announced on December 21st the appointment of Abigail W. Gorman, MBA, as its Chief Executive Officer. Ms. Gorman replaces outgoing CEO Sharon J. Swan, FASAE, CAE, who is retiring after nearly 25 years with ASCPT. During the Board’s review of potential candidates with executive search partner Vetted Solutions, Ms. Gorman’s track record as a successful executive who has served in academic medical and profession-based associations, along with a for-profit strategic consulting services firm distinguished her as the candidate of choice. Ms. Gorman joins ASCPT following her role as Chief of Staff for the American Institute of Architects (AIA). She previously held various leadership positions with the American Dental Education Association (ADEA), culminating in serving as the Deputy Director of ADEA. “I am delighted to welcome Abigail Gorman as the incoming CEO of ASCPT,” said Dr. Mark Dresser, Senior Vice President of Biomarker Sciences and Clinical Pharmacology at Gilead, and President of ASCPT. “With her expertise in finance and business administration and association management, her passion for ASCPT’s mission, and her deep commitment to diversity, equity, and inclusion, we are very fortunate to have Ms. Gorman serve and lead the Society during an unprecedented time of change for professional associations.” The American Society for Clinical Pharmacology & Therapeutics’ mission is to advance clinical pharmacology, translational science, and therapeutics for the benefit of patients and society.

Please click here to view the Full Press Release Announcement.